Alcami, a U.S.-based CDMO, has signed a master laboratory services agreement with Novavax, a biotechnology company developing next-generation vaccines for infectious diseases. Under the agreement, Novavax has immediately secured full-time equivalent (FTE) resources to provide analytical testing support for its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
 
“The large molecule analytical support we have been engaged to provide is a testament to our analytical bandwidth, technical expertise, and ability to collaborate with customers to deliver high-quality results consistently,” said Timothy Compton, Chief Business Officer of Alcami.
 
Alcami’s FTE service offering provides customized solutions to a client’s specific project. The company dedicates multi-discipline resources to a particular project, granting clients additional flexibility and consistent control over their outsourced lab needs.
 
“The addition of Alcami’s analytical expertise to our global manufacturing network will augment our ability to efficiently deliver additional high-quality vaccines to the world,” said Rick Crowley, Executive Vice President, Chief Operations Officer of Novavax. “Our collaboration to date is contributing to our progress in bringing the first protein-based COVID-19 vaccine based on Phase 3 efficacy and safety data.”
 
“We are proud to support Novavax and the important progress they are making against COVID-19,” added Mr. Compton.